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Abstract Huntington’s disease (HD) is a fatal neurodegener-
ative disease caused by an expanded polyglutamine tract in
the huntingtin gene. Therapeutic approaches targeting mutant
huntingtin (mtHtt) or its downstream toxic consequences are
under development, including Rho kinase pathway inhibition.
We investigated the messenger RNA (mRNA) expression of
Rho kinase pathway genes, including RhoA (Ras homolog
family member A), ROCK1 (Rho-associated kinase1),
PRK2 (protein kinase C-related protein kinase 2), Profilin1,
cofilin1, MYPT1 (myosin phosphatase target subunit 1), and
LIMK1 (LIM domain kinase 1) in HD human blood leuko-
cytes, postmortem brain, and in R6/2 HD mouse brain tissue
using qPCR. RhoA, ROCK1, PRK2, Profilin1, cofilin1, and
MYPT1 were significantly increased in HD blood compared
to controls. In frontal cortex of HD postmortem brain tissue,
the expression of RhoA, ROCK1, PRK2, Profilin1, and
MYPT1 were also significantly increased. In the brain from
4-week-old R6/2 mice, the expression of Rock1, Prk2,
Cofilin1, and MYPT1 was significantly increased while
RhoA, Rock1, Profilin1, Cofilin1, and Mypt1 were increased
and Limk1 mRNA decreased in 13-week-old R6/2 mice.
Western blot analysis using human postmortem tissues for
ROCK1 and Profilin1 demonstrated significantly increased
protein levels, which correlated with the mRNA increases.
Collectively, we have shown the panel of Rho kinase pathway
genes to be highly altered in human HD blood, postmortem
brain tissue, and in R6/2 mice. These studies confirm that HD
upregulates the Rho kinase pathway and identifies mRNAs
that could serve as peripheral markers in HD patients and
translational markers in HD mouse models.
Keywords Huntington’s disease . Rho kinase pathway .
mRNA expression . Biomarker
Introduction
Huntington’s disease (HD) is a fatal, autosomal dominant dis-
order caused by a pathologic expansion of CAG repeats in the
IT15 gene, which encodes the ubiquitously expressed
huntingtin protein [1]. HD is characterized clinically by pro-
gressive decline in motor, cognitive, and behavioral function
due to selective neurodegeneration that is especially prominent
in the striatum and cortex [2]. While there are not yet any
disease modifying treatments that have been demonstrated to
delay or slowHD in patients, a number of potential targets have
been identified and validated preclinically in HD models. One
such promising target is inhibition of the Rho kinase pathway,
which reduces mtHtt aggregation, enhances huntingtin clear-
ance, and improves motor function in the R6/2 transgenic mod-
el of HD [3, 4], perhaps by modulating p21-activated kinase1
(Pak1), a downstream target protein of the Rho family that
enhances mtHtt aggregation in cell culture and colocalizes with
mtHtt in postmortem HD brain [5]. The Rho-associated kinase
(ROCK1) inhibitor Y27632 emerged from an in vitro screen
for molecules that reduce polyglutamine toxicity and subse-
quently was shown to reduce huntingtin toxicity and
* Steven Hersch
hersch@helix.mgh.harvard.edu
1 Department of Neurology, MassGeneral Institute for
Neurodegenerative Disease, Harvard Medical School, Massachusetts
General Hospital, East, Bldg 114, Room 2005,
Charlestown, MA 02129-4404, USA
2 Athinoula A. Martinos Center for Biomedical Imaging,
Massachusetts General Hospital, Charlestown, MA 02129, USA
3 Center for Neuroimaging of Aging and Neurodegenerative Diseases,
Massachusetts General Hospital, Charlestown, MA 02129, USA
Mol Neurobiol (2016) 53:2132–2140
DOI 10.1007/s12035-015-9147-9
aggregation in cellular and drosophila models of HD [6, 7] and
to enhance both proteasomal degradation of Htt and
macroautophagy [8, 9]. In genome-wide microarray analyses
of altered gene expression in leukocytes from HD patients, we
identified two Rho kinase pathway messenger RNAs
(mRNAs) amongst those most significantly elevated in HD;
ROCK1 [10] and Cofilin1 [11] suggesting involvement of the
pathway outside of the CNS. To assess the potential of Rho
kinase genes as potential peripheral markers for HD in human
or as pharmacodynamics markers to enable developing treat-
ments targeting the Rho kinase pathway, we used quantitative
real-time PCR of RhoA, ROCK1, PRK2, Profilin1, cofilin1,
MYPT1, and LIMK1 to examine the pathway in more detail in
leukocytes from HD patients as well as in human postmortem
and R6/2 transgenic mouse brain tissue.
Materials and Methods
Antibodies and Reagents
Rock1 antibody (cat#4035, Cell Signaling), Profilin1
(cat#MABT500, Millipore), Cofilin1 (cat#MABT510,
Millipore), beta-actin antibody (Cat#A2066, Sigma), and
anti-rabbit IgG antibody conjugated to horse radish peroxi-
dase were purchased from Abcam. Polyvinyldifluoride
(PVDF) membrane (Bio-Rad) and the enhanced chemilumi-
nescence kit were from Perkin Elmer. All other chemicals
were from Sigma (St. Louis, USA).
Animals
R6/2 transgenic HD mice were obtained from Jackson Labo-
ratories (Bar Harbor, ME). R6/2 mice used in the study were
generated by backcrossing male R6/2 mice with C57BL/6×
CBA F1 female mice. Mice were genotyped by PCR using
tail-tip DNA (CAG repeat length of 135–140). We used wild-
type littermates as controls. Mice were housed with a 12-h
light/dark cycle in a humidity- and temperature-controlled at-
mosphere with ad libitum access to food and water. Mice were
euthanized at the end of 4 and 13 weeks of age. Brains were
removed, and striatum from the brain were dissected, snap
frozen, and used for the RNA extraction. All animal experi-
ments were carried out in accordance with the National Insti-
tutes of Health guidelines for animal research and were ap-
proved by the MGH Animal Care and Use Committee.
Human Blood and Postmortem Brain Tissues
Human Subjects
Banked RNA samples from HD and control subjects partici-
pating in the REVEAL-HD biomarker program at MGH were
used for this study (Table 1). The symptomatic HD patients
had unequivocal motor symptoms based on the Unified
Huntington’s Disease Rating Scale (UHDRS) and a known
trinucleotide repeat expansion. Age and gender-matched con-
trol subjects were volunteers with no significant illnesses,
most of whom were family members of the HD subjects.
Human postmortem brain tissues were obtained from the Tis-
sue Resource Centre of the Alzheimer Disease Research Cen-
ter (ADRC) at Massachusetts General Hospital and Neurolog-
ical Foundation of New Zealand Human Brain Bank, Auck-
land, and were used for this study. Procedures were explained
and consent was obtained according to the Declaration of
Helsinski (BMJ 1991; 302: 1194). Study protocols were ap-
proved by the Partners Internal Review Board (IRB).
RNA Extraction and cDNA Synthesis
RNA Extraction from Human Blood
Whole venous blood was collected directly into Paxgene col-
lection tubes (Paxgene™ Blood RNA Tube, Hombrechtikon,
CH) which contain an RNA-stabilizing additive. Paxgene tubes
as show in Table 1 were processed as previously described [12].
RNA extractions were carried out using the automated
QIAcube system as per the Paxgene procedure including DN-
Ase treatment. RNA quality was assessed using the RNA 6000
NanoChip kit and an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, USA) and spectrophotometry. Complementary DNA
(cDNA) was synthesized using iScript cDNA synthesis kit
(Bio-Rad) as per the manufacturer’s protocol.
RNA Extraction from Postmortem Human Brain and R6/2
Mouse Brain
Total RNA was isolated from 250 to 300 mg of the frontal
cortex from postmortem human brain tissue slices obtained
from the Tissue Resource Centre of the Alzheimer Disease
Research center (ADRC) at Massachusetts General Hospital
and R6/2 and control mouse striatum with 2 ml of TRIZOL
reagent (Invitrogen, Carlsbad, CA, USA) (Table 2). The tissue
was homogenized and RNA extractionwas carried out follow-
ing the manufacturer’s protocol. Two micrograms of total
RNA were used for the reverse transcription following the
Table 1 Clinical characteristics of healthy patients and symptomatic
HD patients
Samples Number Gender Age Mean age
Controls (n=15) 7 Male 32–77 51.1±15.3
8 Female 46–61 52.6±4.9
Symptomatic HD (n=16) 8 Male 48–65 60.6±5.6
8 Female 46–67 55.2±7.3
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DNase elimination procedure. cDNA was synthesized using
iScript cDNA synthesis kit (Bio-Rad).
Real-Time PCR
Briefly, for each gene of interest, primers were designed using
the NCBI primer pick program and the primers were tested
using the relative standard curve method. We used the CFX96
real-time PCR detection system (Bio-Rad). All reactions were
performed in a 15-μl total volume that contained 2.5 μl of
cDNA (1:10 dilution of reverse transcribed samples) and
12.5 μl of PCR reaction mixture containing specific primers
(QuantiTech SYBR Green PCR kit, Qiagen). The primers
used for the human samples and mouse samples are shown
in Tables 3 and 4, respectively. The amplification consisted of
an initial denaturation cycle at 95 °C for 15 min, followed by
45 cycles of 30 s at 94 °C, 30 s at 60 °C, and 30 s at 72 °C.
Specific product formation was confirmed by melting curve
analysis (55–95 °C).
Western Blot Analysis
Briefly, R6/2 mouse brain tissues were homogenized in nine
volumes of lysis buffer containing a protease inhibitor
mixture. After incubation on ice for 30 min, lysates were
briefly sonicated. Protein concentrations were determined
using Bio-Rad DC protein assay reagent (Bio-Rad). Equal
amounts of protein were boiled for 5 min in 6× SDS sample
buffer and then separated by 7.5 % SDS-PAGE and electro-
phoretically transferred to a polyvinylidene difluoride mem-
brane. The membranes were blocked in 5 % skim milk in
0.05 % tween 20 in Tris-buffered saline for 45 min and then
incubated with Rock1 (1:150) primary antibody and beta-
actin primary antibody (1:5000) overnight at 4 °C. The mem-
branes were washed three times in TBS-T and incubated for
1 h with horseradish peroxidase-conjugated secondary anti-
body (1:2000). After the incubation period, the membranes
were washed thrice in TBS-T. Immunoreactive proteins were
detected using enhanced chemiluminescence (Perkin Elmer).
Postmortem human brain tissues obtained from the Neuro-
logical Foundation of New Zealand Human Brain Bank
(Table 2) were homogenized in nine volumes of RIPA buffer
containing a protease inhibitor mixture and tissues were incu-
bated on ice for 10 min. Lysates were spun at 10,000 rpm for
10 min and supernatants were used for the protein estimation.
Equal amounts of protein were boiled for 5 min and then
samples were separated by 7.5 % SDS-PAGE gels for Rock1,
15 % SDS-PAGE gels for Profilin1 and cofilin1. The mem-
brane were blocked in 5 % skim milk in 0.05 % tween 20 in
Tris-buffered saline for 45 min and then incubated with pri-
mary antibodies for Rock1 (1:100), Profilin1 (1:5000),
Cofilin1 (1:1000), or beta-actin (1:10,000) overnight at 4 °C.
The membranes were washed three times in TBS-T and incu-
bated for 1 h with horseradish peroxidase conjugated second-
ary antibody (1:2000). After the incubation period, the
Table 2 Clinical characteristics of postmortem brain tissues of control
and symptomatic HD
Samples Gender Age Mean AGE Postmortem
delay (h)
Controls (n=14) Male and female 41–78 56.3±12.4 7–23
HD (n=14) Male and female 35–74 52.9±10.9 4–19
Table 3 Sequences of the PCR primers for human samples
Gene Orientation Sequence (5′–>3′) Size
(in bp)
RhoA Forward TGAGCACACAAGGCGGGAGC 105
Reverse CACTCCATGTACCCAAAAGCGCCA
ROCK1 Forward GTCTGAGCAGTTGGCGCGAGG 143
Reverse GCATGCTGTTTGCTTCTTCAAG
CCG
PRK2 Forward GCCCTCAAGCTCCTGTGCCTAC 128
Reverse GGCTGGAGGAGGTTCAGGCTCA
Profilin1 Forward GCCGGGTGGAACGCCTACAT 120
Reverse GACGAACGTTTTCCCGGGGACG
Cofilin1 Forward GGCGGTGCTCTTCTGCCTGA 110
Reverse AGGTGGCGTAGGGGTCGTCG
MYPT1 Forward GGACGCGAAGCAGAAGCGGA 119
Reverse AGACGGCGCCATCGTCGAAC
LIMK1 Forward GTGCGAGATCATCGGGCGGG 143
Reverse AACAGCGCACGGTGATGGGG
Beta-actin Forward GGACACCCCACGCCAGTTCG 133
Reverse ACCGTGCGATCCCCATTGGC
Table 4 Sequences of PCR primers for mouse samples
Gene Orientation Sequence (5′–>3′) Size
(in bp)
mRhoA Forward CCGCCTGCGGCCTCTCTCTT 197
Reverse TGGCCAACTCCCGTCTCGTGT
mRock1 Forward AGAAAGAGGACTTGATTTCCCC
GTGC
155
Reverse ACGGACAAAGCCAGATGGTGGG
mPrk2 Forward GTGCCAGTCGTTGACGCACG 112
Reverse CACGAGGTGGGGCTGGAGGA
mProfilin1 Forward CGTAGGCTACAAGGACTCGC 291
Reverse ACACCTTCTTTGCCCATCAG
mCofilin1 Forward CTGGGCCCCCGAGAATGCAC 136
Reverse GGTGCAGCGGTCCTTGACCT
mMYPT1 Forward AAGCGCTCCGTCGTCGTCCT 112
Reverse TCCCCGGGAGTAGGCAGAGGT
mLimk1 Forward CGGAATGTGCCGCTGGACGA 126
Reverse CAGGGGGCTGGGATCCGACA
mBeta-actin Forward ACCGTGAAAAGATGACCCAG 273
Reverse TCTCAGCTGTGGTGGTGAAG
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membranes were washed thrice in TBS-T. Immunoreactive
proteins were detected using enhanced chemiluminescence.
Statistical Analysis
Values are expressed as mean±standard error of the mean. All
the qPCR experiments were performed in quadruplicate. Sta-
tistical analyses were performed using GraphPad Prism ver-
sion 5.0 (GraphPad Software, San Diego, USA) using Stu-
dent’s t test (one-tailed). Results were considered statistically
significant when p 0.05.
Results
Expression Levels of Rho Kinase Pathway Genes
in the Cellular Blood of Patients with HD and in Frontal
Cortex of Postmortem HD Brain
To determine whether Rho kinase pathway genes are altered in
HD,we extracted RNA from age-matched symptomatic HD and
healthy controls blood samples. cDNAs were synthesized and
we carried out qPCR for the panel of genes in the Rho kinase
pathway. We first conducted a preliminary study using a limited
Fig. 1 Expression levels of Rho kinase pathway genes in the cellular
blood of patients with HD and in the frontal cortex of postmortem HD
brain tissues quantified using qPCR. a Levels of RhoA, ROCK1, PRK2,
Profilin1, Cofilin1, and MYPT1 mRNA were significantly increased in
the cellular blood of patients with HD (n=13–15) compared with age- and
gender-matched controls (n=12–14). LIMK1 mRNA levels were not
altered. b Levels of RhoA, ROCK1, PRK2, Profilin1, and MYPT1
mRNA were significantly increased in postmortem brain of individuals
with HD (n=8–9) comparedwith controls (n=5). There was no difference
in expression levels of Cofilin1 or LIMK1. Expression was normalized
with β-actin control. Data were expressed as mean±S.E.M. *p 0.05,
compared with the control
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sample set (n=5–8) and found increases in fold change at
mRNA levels of Rho kinase pathway genes ranges from 1.274
to 1.636 (data not shown). Replication using an independent
sample set with n=13–15, revealed similar results: There were
significant increases in the mRNA levels of RhoA (1.35-fold,
p=0.0289), ROCK1 (1.32-fold, p=0.0296), PRK2 (1.26-fold,
p=0.0378), Profilin1 (1.47-fold, p=0.0202), Cofilin1 (1.63-fold,
p=0.0129), and MYPT1 (1.23-fold, p=0.0306) as shown in
Fig. 1a, suggesting significant modulation of the Rho kinase
pathway in human HD leukocytes. There was no significant
change in mRNA levels of LIMK1 (p=0.3119). To assess
whether the Rho kinase pathway alterations in the blood are
consistent with changes in HD brain, we extracted RNA from
the frontal cortex of postmortem HD brain tissue and controls.
cDNAwas synthesized andwe carried out qPCR for the panel of
genes from the Rho kinase pathway. We found elevated mRNA
Fig. 2 Expression levels of Rho kinase pathway genes in striatum of R6/
2 mouse model of HD in early (4 weeks) and late stage of HD (13 weeks)
quantified using qPCR. a By 4 weeks (early symptomatic), there is a
significant increase in the mRNA levels of Rock1, Prk2, Cofilin1, and
MYPT1 in transgenic R6/2 mice (n=3–5) compared with wild type mice
(n=3–4). No significant difference in mRNA levels of RhoA, Profilin1,
and Limk1. b At 13 weeks (late symptomatic), there are significant
increases in RhoA, Rock1, Profilin1, Cofilin1, and Mypt1 mRNA,
whereas Limk1 mRNA was decreased significantly in transgenic R6/2
mice (n=3–4) compared with wild-type mice (n=3–5). There was no
alteration in Prk2 mRNA levels at 13 weeks. Expression was
normalized with β-actin. Data were expressed as mean±S.E.M. *p
0.05, compared with the control
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levels of RhoA (3.02-fold, p=0.0323), ROCK1 (2.58-fold, p=
0.0081), PRK2 (3.22-fold, p=0.0049), Profilin1 (3.53-fold, p=
0.0267), MYPT1 (2.85-fold, p=0.019) in postmortem brain of
individuals with HD compared with controls (Fig. 1b), suggest-
ing that Rho kinase pathway genes are similarly altered in the
postmortem HD brain tissues. There was no significant differ-
ence in the expression levels of Cofilin1 (p=0.1263) and LIMK1
(p=0.15) in HD brain.
Expression Levels of Rho Kinase Pathway Genes
in Murine Model of HD
To further investigate alterations in Rho kinase pathway genes
in HD, we used qPCR to quantify the mRNA levels of the Rho
pathway genes in the striatum of R6/2 HD mice in early and
late stages of disease progression (4 and 13 weeks) [13]. At
4 weeks, there was already a significant increase in mRNA
Fig. 3 ROCK1, Profilin1, and Cofilin1 protein levels in human postmortem
brain tissues. Western blot analysis of protein levels of a ROCK1, b
Profilin1, and c Cofilin1 and their densitometric quantifications are shown
in (d), (e), and (f) respectively. There is a significant increase in the protein
levels of ROCK1 and Profilin1 compared in HD postmortem brain tissues
(n=14) compared to controls (n=14). A representative Western blot is
shown. There was no significant alteration in Cofilin1 levels. Protein levels
were normalized with β-actin. Data were expressed as mean±S.E.M. *p
0.05, compared with the control
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levels of Rock1 (2.08-fold, p=0.0125), Prk2 (1.89-fold, p=
0.0002), Cofilin1 (1.64-fold, p=0.0002), and MYPT1 (1.62-
fold, p=0.0242) and no significant difference in RhoA (p=
0.0823), Profilin1 (p=0.3022), or Limk1 (p=0.0815) as
shown in Fig. 2a. In late disease, there were significant in-
creases in mRNA levels of RhoA (1.68-fold, p=0.0448),
Rock1 (4.07-fold, p=0.0023), Profilin1 (2.55-fold, p=
0.0001), Cofilin1 (2.21-fold, p=0.0089), and Mypt1 (1.95-
fold, p=0.0153), whereas Limk1 mRNA was decreased sig-
nificantly with a fold change of 0.57 (p=0.0124) in transgenic
R6/2 mice compared with wild-type mice as shown in Fig. 2b.
There was no significant difference in Prk2 mRNA levels in
the late stage (p=0.1288). We observed increased fold chang-
es in mRNA levels for RhoA (0.39-fold), Rock1 (1.99-fold),
Profilin1 (1.44-fold), Cofilin1 (0.57-fold), and Mypt1 (0.33-
fold) comparing older with younger transgenic R6/2 mice.
mRNA levels of Prk2 and Limk1 mRNA levels were de-
creased with fold change of 0.57 and 0.26, respectively.
ROCK1, Profilin1, and Cofilin1 Protein Levels
in the Human Postmortem Brain Tissues
To determine whether the identified mRNA alterations are
translated to altered protein regulation in human HD brain
tissue, we have quantified the protein levels of ROCK1,
Profilin1 and Cofilin1 using Western blot analysis. Small but
significant increases in ROCK1 (p < 0.0001) and Profilin (p =
0.0044) were found in HD compared to controls as shown in
Fig. 3d, e and there was no significant change in cofilin1
protein levels (Fig. 3f).
Rock1 Protein Levels in the Late Stage of R6/2 Mouse
Brain Tissue
To further validate the changes observed in the mRNA levels
of Rho kinase pathway genes, we examined Rock1 protein in
the brain in 13-week-old R6/2 mice and littermate controls.
Western blot analysis revealed there is a significant increase in
Rock1 protein levels in the transgenic R6/2 mice compared to
the wild-type mice as shown in (Fig. 4a) and by its densito-
metric quantification as shown in Fig. 4b.
Discussion
Rho kinases regulate cytoskeletal structural proteins and play
a major role in regulating cell growth, cell structure and dif-
ferentiation, migration, energy conversion, and cell death
Fig. 4 Western blot analysis of Rock1 protein levels in late
stage transgenic R6/2 mouse brain. a Western blot showing Rock1 pro-
tein levels at 13 weeks of age. b Densitometric quantification of Rock1
protein levels from wild type (n=8) and mutant type (n=8) in each group
showed increased levels of Rock1 protein in mutant type compared to
wild type. Data were normalized with β-actin levels. The results were
considered significant when p 0.05
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[14–17]. A potential role for the Rho kinase pathway in the
pathogenesis of HD has also emerged along with its po-
tential as a target for disease modification. Here, we report
a panel of Rho kinase pathway genes (Fig. 5), which are
coordinately upregulated in leukocytes and in the brain in
HD subjects. In R6/2 transgenic mice, we show this same
upregulation in the brain and that it is heightened in later
stages of disease in which additional genes are also upreg-
ulated, suggesting these changes may correlate with pro-
gression. These findings replicate by QPCR and extend
our earlier findings from genome-wide microarray studies
that two Rho kinase pathway genes, ROCK1 [10] and
Cofilin1 [11] are increased in HD leukocytes and suggest
that some of these genes could be a useful source of pe-
ripheral markers of HD progression or of pharmacody-
namic responses to treatments targeting it.
The Rho/Rock pathway primarily regulates actin cytoskel-
etal rearrangements through activation of downstream sub-
strates such as MYPT1, LIM kinases and triggers caspase-
mediated apoptotic cell death via plasma membrane blebbing
[15, 17–19]. Rock can be constitutively activated by pro-
teolytic cleavage of the inhibitory carboxyl terminal do-
main. Rock1 is cleaved by caspase 3 at the cleavage site
DETD1113 during apoptotic condition [18]. Caspase 1
and caspase 3 are transcriptionally upregulated and acti-
vated in transgenic HD mice [20], suggesting that caspase
3 could constitutively activate Rock1 in HD. Previous
studies in HD cell culture models have demonstrated that
Rock1 and protein kinase C-related protein kinase (PRK2)
are involved in mediating mtHtt aggregate formation and
Rock inhibition decreases aggregation [9]. Considering
these factors together, the upregulation of the Rho/Rock
pathway may mediate phosphorylation of its downstream
targets which signal toward apoptotic cell death. However,
it is unclear how Rho/Rock pathway is transcriptionally
regulated in HD pathogenesis.
In HD leukocytes, Rock1 and Profilin1 had fold changes of
1.32 and 1.47, respectively, while cofilin1 had the highest fold
change of 1.63, sufficient differences to serve as potential
peripheral markers of HD clinically. Rho kinase pathway gene
upregulation in HD postmortem brain tissues paralleled those
in the blood and had even higher fold changes (up to 2.58 for
Rock1 and 3.58 for Profilin1) suggesting that mtHtt affects the
Rho kinase pathway similarly in the brain and blood. In addi-
tion to increased mRNA levels of ROCK1 and Profilin1, we
observed modest, but significant upregulation of the protein
levels in human postmortem brain. These genes could thus
usefully mark target engagement by potential treatments in
the blood from research subjects and in mouse tissue in trans-
lational studies. Future studies with larger cross-sectional and
longitudinal patient sample sets are necessary to examine
whether the expression of these genes, either individually or
as a panel, can mark the HD prodrome, clinical onset, or
disease progression. Additional studies using R6/2 HD mice
treated with Rho kinase inhibitors could help validate these
genes as pharmacodynamic markers.
In conclusion, the present study shows that the presence
of mutant huntingtin causes increased expression levels of
Rho/Rock kinase pathway genes in HD leukocytes, postmor-
tem brain tissues, and in R6/2 HD mice. However, more
studies are necessary to clearly understand the precise mo-
lecular mechanism of upregulation of this pathway in HD
pathogenesis, and to further validate its potential for provid-
ing novel biomarkers and disease-modifying therapeutic tar-
gets for HD.
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